
📣 Catch up on data from #ESMO26! Drs @LizzySmyth1 & @YJanjigianMD share expert insights on new phase 3 gastric/GEJ cancer data from: 🔸 CLARITY-Gastric 01 (CG-01): a phase 3 study of sonesitatug vedotin in 2L+ advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. Xu R-H, et al. Abstract LBA7, ESMO 2026 🔸 G-HOPE-001: First interim analysis of the phase 3 study of arcotatug tavatecan (IBI343/TAK-921) vs treatment of physician’s choice in previously treated advanced gastric/GEJ adenocarcinoma. Shitara K, et al. Abstract LBA77, ESMO 2026 📹 Watch their clinical takeaways in this post Watch the full update: cor2ed.com/n-connect/program… 🤝 Endorsed by @ESDO_tweets Supported by an Independent Educational Grant from AstraZeneca. In Spain, the information displayed is exclusively directed to Healthcare Professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public. This content is intended for HCPs only. #MedEd #GIcancer #gastric #GEJ #OncTwitter #Medtwitter












